Anvumetostat is an investigational new drug that is being developed by Amgen for the treatment of methylthioadenosine phosphorylase (MTAP)-null solid tumors. Anvumetostat acts as a PRMT5 inhibitor.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.